Please login to the form below

Not currently logged in
Email:
Password:

Roche nominates Dr Claudia Süssmuth Dyckerhoff to board

She is set to replace Professor Dr Beatrice Weder di Mauro

Roche - Basel, SwitzerlandRoche's board of directors have lined up Dr Claudia Süssmuth Dyckerhoff to replace Professor Dr Beatrice Weder di Mauro, who has decided to not stand for re-election at the company's annual general meeting in March.

Weder di Mauro has been a member of the board since 2006 and also served on its audit committee.

Dyckerhoff is currently senior partner at McKinsey & Company and sector leader Asia health services and systems.

Christoph Franz, chairman of Roche, said: “As a member of the board and the audit committee, Beatrice Weder di Mauro has made significant contributions to Roche's success with her broad expertise in economics.”

He added: “I am delighted with our nomination of Claudia Süssmuth Dyckerhoff for election as a new member of the board. She is a leader with extensive international experience in strategic consultancy in the healthcare industry, especially in Asian growth markets.”

7th January 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
wethepeople

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics